M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m

ScienceDirect

w w w . e l s e v i e r . c o m / l o c a t e / m o l o n c

Preclinical validation of anti-nuclear factor-kappa B therapy
to inhibit human vestibular schwannoma growth

Sonam Dilwalia,b, Martijn C. Bri‚Ç¨eta,d, Shyan-Yuan Kaoa, Takeshi Fujitaa,c,
Lukas D. Landeggera,c, Michael P. Plattc,e, Konstantina M. Stankovica,b,c,*
aEaton Peabody Laboratories, Department of Otolaryngology, 243 Charles Street, Massachusetts Eye and Ear
InÔ¨Årmary, Boston, MA 02114, USA
bHarvard-MIT Program in Speech and Hearing Bioscience and Technology, 77 Massachusetts Avenue, Cambridge,
MA 02139, USA
cDepartment of Otology and Laryngology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
dDepartment of Otorhinolaryngology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden,
The Netherlands
eDepartment of Otolaryngology-Head and Neck Surgery, Boston University, 72 E Concord Street, Boston,
MA 02118, USA

A R T I C L E

I N F O

A B S T R A C T

Article history:
Received 12 August 2014
Received in revised form
22 February 2015
Accepted 23 March 2015
Available online -

Keywords:
Vestibular schwannoma
Network analysis
NF-kB
TNF
BAY 11-7082
Curcumin

Vestibular schwannomas (VSs), the most common tumors of the cerebellopontine angle,
arise from Schwann cells lining the vestibular nerve. Pharmacotherapies against VS are
almost non-existent. Although the therapeutic inhibition of inÔ¨Çammatory modulators
has been established for other neoplasms, it has not been explored in VS. A bioinformatic
network analysis of all genes reported to be differentially expressed in human VS revealed
a pro-inÔ¨Çammatory transcription factor nuclear factor-kappa B (NF-kB) as a central mole-
cule in VS pathobiology. Assessed at the transcriptional and translational level, canonical
NF-kB complex was aberrantly activated in human VS and derived VS cultures in compar-
ison to control nerves and Schwann cells, respectively. Cultured primary VS cells and VS-
derived human cell line HEI-193 were treated with speciÔ¨Åc NF-kB siRNAs, experimental NF-
kB inhibitor BAY11-7082 (BAY11) and clinically relevant NF-kB inhibitor curcumin. Healthy
human control Schwann cells from the great auricular nerve were also treated with BAY11
and curcumin to assess toxicity. All three treatments signiÔ¨Åcantly reduced proliferation in
primary VS cultures and HEI-193 cells, with siRNA, 5 mM BAY11 and 50 mM curcumin
reducing average proliferation (standard error of mean)
to 62.33%  10.59%,
14.3  9.7%, and 23.0  20.9% of control primary VS cells, respectively. These treatments
also induced substantial cell death. Curcumin, unlike BAY11, also affected primary
Schwann cells. This work highlights NF-kB as a key modulator in VS cell proliferation
and survival and demonstrates therapeutic efÔ¨Åcacy of directly targeting NF-kB in VS.
¬™ 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.

Abbreviations: BAY11, BAY 11-7082; GAN, great auricular nerve; IkBa, inhibitor of kappa B alpha; Ikk, inhibitor of kappa B alpha kinase;
NF-kB, nuclear factor-kappa B; SC, Schwann cell; TNF, tumor necrosis factor; VS, vestibular schwannoma.
* Corresponding author. 243 Charles St., Boston, MA 02114, USA. Tel.: √æ1 617 573 3972; fax: √æ1 617 720 4408.
E-mail addresses: sdilwaliutsw@gmail.com (S. Dilwali), martijnbriet@gmail.com (M.C. Bri‚Ç¨et), Shyan-Yuan_Kao@meei.harvard.edu
(S.-Y. Kao), takeshi_fujita@meei.harvard.edu (T. Fujita), Lukas_landegger@meei.harvard.edu (L.D. Landegger), Michael.Platt@bmc.org
(M.P. Platt), konstantina_stankovic@meei.harvard.edu (K.M. Stankovic).
http://dx.doi.org/10.1016/j.molonc.2015.03.009
1574-7891/¬™ 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

2

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

1.

Introduction

surgical

resection and stereotactic

Vestibular schwannomas (VSs) are the fourth most common
intracranial tumors (Mahaley et al., 1990). Although histolog-
ically non-malignant, they can cause multiple cranial neu-
ropathies and even death due to their location in the
cerebellopontine angle and potential for brainstem compres-
sion. Currently, main treatment modalities for growing VSs
are
radiotherapy.
Although interest
in pharmacotherapies against VS is
increasing (Plotkin et al., 2012), none are FDA approved.
This is partially because drugs such as bevacizumab, which
shrink some VSs, have substantial side effects, including
renal
failure, which may outweigh potential beneÔ¨Åts
(Plotkin et al., 2012). Therefore, there is an unmet medical
need to establish well-tolerated pharmacotherapies to pre-
vent VS growth. Although much is known about the different
pathways implicated in VS pathobiology, the interconnec-
tedness among these pathways has not been studied
extensively.

To identify the major orchestrators of VS growth, we con-
ducted the Ô¨Årst comprehensive network analysis of the pub-
lished genes aberrantly expressed in sporadic VS. Nuclear
factor-kappa B (NF-kB), a transcription factor known for medi-
ating the physiological inÔ¨Çammatory response and pathologic
inÔ¨Çammation in several diseases, including neoplastic growth
(Hoesel and Schmid, 2013), was identiÔ¨Åed as a central factor in
a top-ranking network. Although NF-kB has been connected to
other molecules in VS, NF-kB activation and the accompa-
nying inÔ¨Çammation have not been directly explored as thera-
peutic targets against sporadic VS. However,
level of
inÔ¨Åltration of CD163√æ tumor-associated macrophages, known
to pathologically promote tumor growth and survival, corre-
lates with human VS growth rate, motivating research to
investigate the inÔ¨Çammatory pathways that may promote
VS growth (de Vries et al., 2013).

NF-kB can regulate the transcription of over 300 down-
stream genes, resulting in differential
inÔ¨Çuences on cell
growth, proliferation and survival depending on the stimulus
(Gilmore, 2014). NF-kB‚Äôs therapeutic inhibition has been inves-
tigated in several cancers because of its role in pathological
inÔ¨Çammation accompanying neoplastic growth (Hoesel and
Schmid, 2013). NF-kB is especially relevant for VS since merlin,
the protein encoded by the NF2 gene, acts as a negative regu-
lator of the NF-kB pathway (Kim et al., 2002) and merlin is
dysfunctional in majority of VSs (Lee et al., 2012a,b). Addition-
ally, Axl, a member of the TAM family of receptor tyrosine ki-
nases, regulates overexpression of survivin and cyclin D1
through NF-kB,
leading to enhanced survival, cell-matrix
adhesion and proliferation of cultured VS cells (Ammoun
et al., 2013). NF-kB also regulates p75-associated VS prolifera-
tion and apoptosis (Ahmad et al., 2014).

We investigated NF-kB‚Äôs aberrance in human VS and the
therapeutic potential of NF-kB inhibition. Our results sug-
gest that the NF-kB pathway is aberrantly activated in VS
and VS-derived cultures compared to healthy nerves and
SCs, respectively. NF-kB inhibition in primary VS cells and
a VS-derived human cell line using NF-kB siRNA, an experi-
mental NF-kB inhibitor BAY 11-7082 (BAY11) and a clinically

relevant inhibitor curcumin decreased proliferation and
survival of the tumor cells. Our work provides novel insight
into NF-kB‚Äôs expression and role in VS pathobiology and
demonstrates therapeutic efÔ¨Åcacy of directly targeting NF-
kB in VS.

2.

Materials and methods

2.1.

Ingenuity Pathway Analysis

assay,

enzyme-linked

immunosorbent

A literature search was performed with PubMed using MeSH
terms neuroma, acoustic, proteins, genes, gene expression,
gene expression regulation, gene expression proÔ¨Åling, micorar-
ray analysis, DNA mutational analysis, immunohistochem-
istry,
tumor
suppressor proteins, DNA and RNA. Only human studies with
relevant controls and explicit description of statistical criteria
were selected. Differentially expressed molecules were
analyzed on April 14th 2011 using Ingenuity Pathway Analysis
(IPA, Ingenuity Systems, Inc.) version 9.0, while setting a cutoff
value to 2. Molecules reported to be up- or down-regulated
qualitatively were assigned a value 2 or  2, respectively. To
avoid a bias toward molecules with extreme differential
expression, the absolute maximal value for fold change was
set to 100 for molecules with a greater change. The maximal
number of molecules per network was 35. The most intercon-
nected molecule in each network is known as the hub.

2.2.

Specimen collection

Freshly harvested human specimens of sporadic VS and con-
trol great auricular nerve (GAN) were collected from indicated
surgeries, placed in saline and transported to the laboratory
on ice. The study protocols were approved by Human Studies
Committee of Massachusetts General Hospital and Massachu-
setts Eye and Ear InÔ¨Årmary, and conducted in accordance with
the Helsinki Declaration.

2.3.

Real time quantitative polymerase chain reaction

Expression of genes in the NF-kB pathway was measured us-
ing real time quantitative PCR (qPCR). Human VS or GAN tis-
sue was placed in RNA Later (Qiagen) temporarily. RNA was
extracted using RNeasy Mini-Kit
(Qiagen) and reverse-
transcribed to cDNA with Taqman Reverse Transcription Re-
agent kit
(Applied Biosystems), as previously described
(Stankovic et al., 2009). qPCR was performed using Applied
Biosystems 7700 Sequence Detection System with TaqMan
Primers (Applied Biosystems) for NFKB1 (encoding p50 subunit
of the NF-kB heterodimer, Hs01042010_m1), RELA (encoding
p65 subunit of the NF-kB heterodimer required for activation,
Hs01042010_m1), TNF (encoding tumor necrosis factor, an
inducer for NF-kB, Hs01042010_m1), RANK (encoding receptor
activator of nuclear factor-kappa B, Hs00187192_m1), NFKB2
RELB
(Hs01028901_g1),
(Hs00232399_m1) and for downstream genes with kB sites,
namely CCND1 (encoding cyclin D1, Hs00765553_m1), BCL2
lymphoma 2, Hs00608023_m1), CSF2
(encoding B-cell

(Hs00968440_m1),

and

REL

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

3

(encoding

(encoding colony stimulating factor 2, Hs00929873_m1), and
XIAP
apoptosis,
Hs00745222_s1). The reference gene was ribosomal RNA 18S
(Hs9999901_s1).

inhibitor

X-linked

of

2.4.

Protein extraction and quantiÔ¨Åcation



Translation and activation of the NF-kB pathway components
were investigated through western blot analysis. Total protein
was extracted on ice from freshly harvested specimens of VS
and GAN in RIPA buffer supplemented with protease and
phosphatase inhibitors (Roche Applied Sciences). The lysate
was isolated by centrifugation and stored at  80
C. Equal pro-
tein was loaded per lane, separated on a 4e20% Tris-glycine
gel (Invitrogen) and transferred onto a Polyvinylidene Ô¨Çuoride
membrane (Millipore). The membrane was blocked and
probed with Cell Signaling Technology antibodies against
NF-kB phosphorylated (P-) p65 (#3033), NF-kB p65 (#8242), in-
hibitor of kappa B alpha (IkBa, #11930) or NF-kB p50 (Abcam,
#ab7971), followed by secondary antibodies (Jackson-Immuno
Research). Membranes were visualized with ChemiDoc XRS√æ
(Bio-Rad Laboratories). Band densities were quantiÔ¨Åed using
ImageJ and normalized to GAPDH expression (Cell Signaling
Technology, #5174).

2.5.

Immunohistochemistry

Human VS and GAN specimens were Ô¨Åxed in 4% PFA, trans-
ferred to PBS, embedded in parafÔ¨Ån, sectioned, deparafÔ¨Ånized
with xylene, washed in PBS, permeabilized with Triton-X 100
(Integra) for 5 min, blocked in normal horse serum and incu-
bated with primary antibodies against S100 (Dako, #Z0311)
or p50 (Abcam, #ab7971) and corresponding Ô¨Çuorescent sec-
ondary antibodies (Jackson-Immuno Research). Nuclei were
labeled with Hoechst stain (Invitrogen). The tissue was visual-
ized and imaged using Carl Zeiss 2000 upright microscope.

Primary human Schwann cell and vestibular

2.6.
schwannoma cell culture

Using sterile technique, freshly harvested VS or GAN tissue
was rinsed in PBS, dissected in culture medium consisting of
Dulbecco‚Äôs ModiÔ¨Åed Eagle‚Äôs medium with Ham‚Äôs F12 mixture
(DMEM/F12), 10% fetal bovine serum, 1% Penicillin/Strepto-
mycin (Pen/Strep) and 1% GlutaMAX, dissociated in Hyaluron-
idase and Collagenase (all from Life Technologies) overnight
and cultured for 2e4 weeks, as previously described (Dilwali
et al., 2014). Human VS cell line HEI-193, derived from a patient
with neuroÔ¨Åbromatosis type 2 (NF2), was obtained from Dr.
Giovanni at the House Ear Institute (Hung et al., 2002a,b).

from Life Technologies). The vehicle used for siRNA delivery
was RNAiMax (#13778030, Life Technologies). Some cultures
were incubated with a Ô¨Çuorescent red oligo (Life Technologies)
with vehicle to assess transfection efÔ¨Åciency.

For pharmacologic treatment, cultured primary VS cells,
primary SCs and HEI-193 cells were treated for 48 h with NF-
kB inhibitors BAY 11-7082 (BAY11, #sc-200615) or curcumin
(#sc-200509A)
(both purchased from Santa Cruz Biotech-
nology) in media fortiÔ¨Åed with antibiotics and serum. BAY11
or curcumin, diluted in 100% DMSO, were mixed to the accu-
rate concentrations in media and applied to the cultures
(with DMSO concentration in media being 1% maximum),
alongside no treatment (NT) with DMSO alone.

2.8.

QuantiÔ¨Åcation of proliferation and apoptosis

0



After treatment, proliferation or apoptosis was assessed as
previously detailed (Dilwali et al., 2014). BrieÔ¨Çy, cell prolifera-
-Deoxyuridine
tion was quantiÔ¨Åed by adding 5-Bromo-2
(BrdU, Invitrogen) to the cultured cells 20 h prior to Ô¨Åxation.
Primary antibodies against BrdU (AbD Serotec, #OBT0030G),
S100 (Dako, #Z031129), or p50 (Abcam, #ab7971) were used.
For assessing apoptosis, terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL, Roche Applied Sci-
C and 0.5 h at RT on the
ences) was applied for 1 h at 37
shaker after Ô¨Åxation and permeabilization. Cells were counted
by an investigator (S.D.) blinded to the treatment conditions.
Cells were counted in 3 Ô¨Åelds. Cell proliferation and
apoptosis were reported as percent BrdU positive and TUNEL
positive nuclei, respectively. As a validation for TUNEL stain-
ing, apoptosis was also assessed using immunocytochemistry
by the expression of cleaved caspase-3 in cells treated with
siRNA or curcumin. Antibody against cleaved caspase-3 (Cell
Signaling Technology, #9661) was utilized. The inhibitors
were compared to the control group by normalizing the
percent change in proliferation or percent of apoptosis in
comparison to the non-treated cells.

2.9.

Electrophoretic mobility shift assay (gel shift assay)

The gel shift assay was performed using the LightShift Chemi-
luminescent EMSA Kit (Thermo ScientiÔ¨Åc, #20148) according
to the manufacturer‚Äôs manual. The 6% DNA retardation gels
and biotin labeled NF-kB binding site oligos (sense: 5
-AGTT-
0
0
-
GAGGGGACTTTCCCAGGC-biotin-3
0
), and non-labeled
TCAACTCCCCTGAAAGGGTCCG-biotin-3
oligos were purchased from Invitrogen. The nuclear extract
of VS tumors and control GAN tissues were puriÔ¨Åed using
the Nuclear Extraction Kit (Abcam, #ab113474).

anti-sense:

and

5

0

Pharmacologic treatment of VS cultures with BAY

2.7.
11-7082, curcumin and siRNA

2.10.

Statistical analyses

For siRNA treatment, cultured primary VS cells or HEI-193
cells were placed in antibiotic- and serum-free media over-
night as instructed by manufacturer. The next day, the cells
were incubated with siRNAs targeting NF-kB genes RELA
(#s11915) and NFKB1 (#s9504), with control cells being treated
with scrambled siRNA (#TR30015), for 5 days (all purchased

Networks from IPA were statistically analyzed with the right-
tailed Fisher‚Äôs exact test; p < 0.05 was considered signiÔ¨Åcant.
For qPCR, western blot and treatment of cultured cells, two-
tailed t-test was used to assess signiÔ¨Åcance with a p < 0.05
considered signiÔ¨Åcant after a Benjamini-Hochberg correction
for multiple hypotheses.

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

4

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

3.

Results

Network analysis reveals nuclear factor-kappa B

3.1.
(NF-kB) as a central modulator of VS growth

Of the 622 articles identiÔ¨Åed, 19 met our inclusion criteria
(Aarhus et al., 2010; Archibald et al., 2010; Bian et al., 2005;
Caye-Thomasen et al., 2010; CiofÔ¨Å et al., 2010; Dayalan et al.,
2006; Doherty et al., 2008; Kramer et al., 2010; Lassaletta
et al., 2009; O‚ÄôReilly et al., 2004; Patel et al., 2008; Plotkin
et al., 2009; Sawaya and Highsmith, 1988; Saydam et al.,
2011; Seol et al., 2005; Stankovic et al., 2009; Szeremeta et al.,
1995; Thomas et al., 2005; Welling et al., 2002), generating
221 molecules eligible for network analysis: 162 overexpressed
and 59 underexpressed molecules in sporadic VS. IPA gener-
ated a total of 19 networks. Supplementary Table S1 shows
the hubs of the top 14 networks. Here we focus on validation

of the hub of the second most signiÔ¨Åcant network (p ¬º 10
 33,
Figure 1). We focus on NF-kB because it is a key pro-
inÔ¨Çammatory transcription factor that could be an important
therapeutic target in VS (Ammoun et al., 2013), and TNFa, an
inducer of NF-kB, was the hub of another top-ranking network
(Supplementary Table S1).

Vestibular schwannomas have aberrant expression

3.2.
and activation of the canonical NF-kB pathway

The canonical and non-canonical NF-kB pathways were inves-
tigated in VS compared to GAN using qPCR, western blot and
immunohistochemistry. The qPCR data are expressed as the
average with range of expression in parentheses and ‚Äún‚Äù indi-
cating the number of different tumors or control nerves. In the
canonical pathway, expression of genes NFKB1 (encoding the
p50 subunit) and RELA (encoding the p65 subunit) tended to

L33) that connects molecules reported to be upregulated (green) or downregulated (red) in VS with
Figure 1 e A highly signiÔ¨Åcant network (p [ 10
other molecules from IPA (white). The hub of this network is nuclear factor-kappa B (NF-kB) complex. Solid lines represent direct and dashed
lines represent indirect interactions.

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

5

Figure 2 e NF-kB is aberrantly activated in VS. A. NF-kB pathway expression in human VSs (n ‚Ä° 9 tumors) versus GANs (n ‚Ä° 8 nerves) as
measured through qPCR. Dashed lines separate genes by groups, being genes associated with canonical NF-kB pathway, non-canonical NF-kB
pathway and downstream targets of NF-kB. Error bars represent range. B. NF-kB pathway expression in human VSs (n ‚Ä° 4) versus GANs (n ‚Ä° 4)
as quantiÔ¨Åed through western blot analysis. P-means phosphorylated protein. Dashed line separates canonical and non-canonical proteins. Error
bars represent SD. C. Representative images of p50 expression (red), as visualized through immunohistochemistry, in (a) VS and (b) GAN
specimens. Schwann or schwannoma cells are labeled with S100 (green). D. Representative image of CD163 expression (red), schwannoma cells
(S100, green). GAN and VS expression is shown in black and gray bars, respectively (A, B). *p < 0.05, **p < 0.01. Nuclei are labeled with Hoechst
(blue) in (C, D). E. Gel shift results show interaction between nuclear extracts of GAN tissue (pooled from 6 different patients, lanes 2e3) or VS
tissue (pooled from 4 different patients, lanes 5e6) with the NF-kB binding site. The interaction could be disrupted in VS nuclear extracts by
adding excessive unlabeled NF-kB binding site (lane 6).

be higher in VSs (n ¬º 10) compared to GANs (n ¬º 10), albeit not
signiÔ¨Åcantly, with p ¬º 0.18 and 0.17, respectively (Figure 2A).
Non-canonical components REL, RELB and NFKB2 exhibited
different patterns of expression. REL was 3.1 (1.0e9.4) fold
higher in VSs (n ¬º 13) than in GANs (n ¬º 10) (p ¬º 0.01,
Figure 2A). NFKB2 had the same average expression in VSs

as GANs (p ¬º 0.22, Figure 2A). Interestingly, RELB was 0.4
(0.2e1.0) fold downregulated in VSs (n ¬º 13) compared to
GANs (range 0.5e2.1, n ¬º 10) (p ¬º 0.02, Figure 2A).

Exploring the downstream genes with kB binding sites by
qPCR, two genes under canonical NF-kB control were signiÔ¨Å-
cantly upregulated in VSs (n ¬º 15) relative to GANs (n ¬º 15):

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

6

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

pro-proliferative CCND1 at 8.1 (5.7e11.5) fold (p ¬º 0.0007) and
anti-apoptotic BCL2 at 4.9 (3.3e7.1) fold (p ¬º 0.02, Figure 2A).
The ranges in GAN were 0.7e1.4 and 0.8e1.3 for CCND1 and
BCL2, respectively. Anti-apoptotic XIAP was equally expressed
in VSs (n ¬º 12) and GANs (n ¬º 7) (p ¬º 0.18, Figure 2A). Pro-
proliferative CSF2 tended to be downregulated, albeit not
signiÔ¨Åcantly (p ¬º 0.11, Figure 2A), in VSs (n ¬º 9) compared to
GANs (n ¬º 7).

Upstream regulator of the canonical NF-kB pathway, gene
TNF encoding TNFa, was expressed at 11.7 (7.9e17.4) fold
higher levels in VSs (n ¬º 10) than in GANs (range 0.7e1.5,
n ¬º 10) (p ¬º 0.003, Figure 2A). Upstream regulator of the non-
canonical NF-kB pathway, RANKL gene TNFS11 tended to be
downregulated in VSs (n ¬º 10) than in GANs (n ¬º 10), although
not signiÔ¨Åcantly (p ¬º 0.20, Figure 2A).

Following qPCR, NF-kB translation and activation were
assessed. Western blot analysis revealed that NF-kB canonical
pathway was substantially activated in VSs compared to
GANs. TNFa activates inhibitor of kappa B kinase (Ikk), which
phosphorylates inhibitor of kappa B alpha (IkBa), enabling the
heterodimer of NF-kB p65 and p50 to phosphorylate and relo-
cate to the nucleus to promote transcription of genes impor-
tant for survival and proliferation (Karin, 1999). Western blot
data are summarized as average fold change  standard devi-
ation, with ‚Äún‚Äù indicating the number of different tumors or
nerves. The representative western blot results are shown in
Supplementary Figure S1 and the statistical results are shown
in Figure 2B. The internal control protein, GAPDH, was not
signiÔ¨Åcantly different between VSs and GANs (p ¬º 0.36). NF-
kB p65 (encoded by the RELA gene) and p105 (encoded by the
NFKB1 gene) had an insigniÔ¨Åcant trend of being more abun-
dant in VSs (n ¬º 7e10) than in GANs (n ¬º 7e9), with p ¬º 0.09
and ¬º 0.14, respectively (Figure 2B). The phosphorylated
form of p65 was 4.2  3.1 fold more expressed in VSs (n ¬º 9)
compared to GANs (n ¬º 8, p ¬º 0.03, Figure 2B). p105‚Äôs derived
subunit p50 likewise showed tendency for higher expression,
albeit non-signiÔ¨Åcant, in VSs (n ¬º 15) compared to GANs
(n ¬º 11, p ¬º 0.10, Figure 2B). NF-kB‚Äôs canonical inducer,
TNFa, was 5.4  0.7 fold more abundant in VS (n ¬º 4) than in
GAN (n ¬º 4, p ¬º 0.001, Figure 2B), demonstrating the same
trend as seen through qPCR. The phosphorylated form of
IkBa was also 2.8  0.8 fold higher in VSs (n ¬º 4) than in
GANs (n ¬º 4, p ¬º 0.01, Figure 2B).

The expression of NF-kB non-canonical proteins c-Rel
(encoded by REL gene) and p100 (encoded by NFKB2 gene)
mirrored the corresponding mRNA expression: c-Rel was
3.6  0.8 fold more expressed in VSs (n ¬º 7) than in GANs
(n ¬º 7, p ¬º 0.003, Figure 2B). p100 was not different in VSs
(n ¬º 4) compared to GANs (n ¬º 4, p ¬º 0.42, Figure 2B). Interest-
ingly, expression of Rel B protein (encoded by RELB) was
signiÔ¨Åcantly, 3.3  1fold higher in VSs (n ¬º 7) than in GANs
(n ¬º 7, p ¬º 0.006), demonstrating the opposite trend from the
corresponding mRNA. Taken together, these results demon-
strate presence and basal activation of NF-kB in GANs and
VSs, and consistently higher activation of the canonical NF-
kB pathway in VSs.

Immunohistochemistry in 5 different VS and 4 different
GAN samples veriÔ¨Åed that NF-kB was active in VS as the
p50 subunit
in VS specimens
(Figure 2C (b)), thus corroborating the western blot results

localized to the nuclei

demonstrating a higher level of phosphorylation, and hence
activation of NF-kB in VSs. GAN specimens showed minimal
p50 nuclear localization although p50 was present in the cyto-
plasm (Figure 2C (a)). S100, a marker for SCs, highlights
schwannoma cells in VS specimens and SCs encasing the
nerve Ô¨Åbrils in GANs (Figure 2C (a)). Additionally, CD163-
positive tumor-associated macrophages were present in the
same VSs at substantially higher levels than in GANs
(Figure 2D), indicating an aberrant inÔ¨Çammatory presence in
VS as described previously (de Vries et al., 2013). Taken
together, our results demonstrating activation of p50 and
several other proteins associated with NF-kB in VS expand
on the previous Ô¨Ånding of p65 activation in VS cells
(Ammoun et al., 2013).

To further conÔ¨Årm the activation of the NF-kB pathway in
VS tissues, the gel shift assay was performed and the DNA
binding activities in VS tissues and GAN tissues were
compared. To provide enough nuclear extracts for the assay,
VS tissues were pooled from 4 patients and GAN tissues
were pooled from 6 patients. The binding of NF-kB p65-p50
heterodimer to its binding site was avid in the VS nuclear
extract and not detectable in the GAN nuclear extract
(Figure 2E). The interaction in the VS nuclear extract could
be blocked by adding the excess non-labeled oligos containing
the NF-kB binding site (Figure 2E, lane 6). These results indi-
cate that the NF-kB activity was speciÔ¨Åcally elevated in VS
tissues.

SpeciÔ¨Åc NF-kB knockdown decreases proliferation

3.3.
and survival of VS cultured cells

The NF-kB canonical pathway was also expressed and acti-
vated at signiÔ¨Åcantly higher levels in primary VS cultures
(n ¬º 6 different tumors) compared to SC cultures (n ¬º 6
different nerves) (Figure 3A). NF-kB p65 and its phosphory-
lated form had 1.9  0.4 fold (p ¬º 0.01) and 2.8  0.4 fold
(p ¬º 0.02) higher expression in VS cells compared to SCs,
respectively. NF-kB p105 and its derived subunit p50 were pre-
sent in cultures, although not at signiÔ¨Åcantly higher levels
than in SCs (p ¬º 1.0 and p ¬º 0.06, respectively, Figure 3A).

Applying siRNAs targeting RELA and NFKB1 concurrently
decreased proliferation, as measured by nuclear BrdU stain-
ing, and cell survival, as measured by the TUNEL assay. Re-
sults are summarized as average  standard error of mean
(SEM), with ‚Äún‚Äù referring to the number of cultures from
different specimens. Proliferation changes are normalized to
each culture‚Äôs proliferation rate. Transfection efÔ¨Åciency of
approximately 94  3% was achieved in primary VS cells
(n ¬º 3), as assessed by transfection of a Ô¨Çuorescent red-
labeled oligo (Figure 3B). The siRNA-mediated knockdown of
NFKB1 and RELA in VS cells was detected using western blot
and the results are shown in Supplementary Figures S2A
and S2B, respectively. Basal proliferation in VS cultures
treated with scrambled siRNA was 6.5%  2.6% (n ¬º 4,
Figure 3C (a), D). Proliferation signiÔ¨Åcantly decreased to
62.33%  10.59% after siRNA treatment (n ¬º 4, p ¬º 0.025,
Figure 3C (b), D). Percentage of VS cells treated with scrambled
siRNA only exhibiting TUNEL staining was 8.59%  4.92%
(n ¬º 3, Figure 3E (a), F). Apoptosis tended to increase, although
insigniÔ¨Åcantly, to 27.54%  20.53% in VS cultures treated with

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

7

Figure 3 e NF-kB is aberrantly activated in primary VS cultures and its siRNA-mediated knockdown decreases proliferation. A. NF-kB expression
in cultured human VSs (n ‚Ä° 6 tumors) normalized to expression in SC cultures (n ‚Ä° 6 nerves) as quantiÔ¨Åed through western blot analysis. P-means
phosphorylated protein. Error bars represent SD. B. Representative image of effective transfection of a Ô¨Çuorescently labeled oligonucleotide (oligo,
red) in primary VS cells. C. Representative proliferation images are shown for (a) scrambled siRNA or (b) siRNA treated primary VS cells. BrdU in
nuclei (red) marks proliferating cells. D. QuantiÔ¨Åcation of proliferation changes after siRNA treatment in primary VS cells normalized to
proliferation in control scrambled siRNA treated (NT) cells (n [ 4 results were from 4 independent results from cultures of two different patients).
E. Representative cell death images are shown for (a) scrambled siRNA and (b) siRNA treated primary VS cells. TUNEL (green) in nuclei marks
dying cells. F. QuantiÔ¨Åcation of cell death rate after siRNA treatment of primary VS cells as measured by TUNEL staining (n [ 3 different
cultures). Error bars represent SD for panels D and F. *p [ 0.025, re [ compared to. Nuclei are labeled with Hoechst (blue) in (C, E).

NF-kB siRNA (n ¬º 3, p ¬º 0.53, Figure 3E (b), F). Similar results
were also observed using anti-cleaved caspase-3 immunocy-
tochemistry. NF-kB siRNA transfection in VS increased the
percentage of cells that expressed cleaved caspase-3 from
2.01%  1.24% to 7.44%  7.15%; however, the difference was
not statistically signiÔ¨Åcant (n ¬º 3, p ¬º 0.13, Fig S3A).

NF-kB small-molecule inhibitor BAY 11-7082

3.4.
decreases proliferation and survival selectively in primary
VS and HEI-193 cells

Primary VS cells, control SC cultures and the HEI-193 cell line
were treated with BAY11. BAY11 treatment signiÔ¨Åcantly
decreased the activity of the NF-kB pathway as shown by the
decrease of phosphorylated p65 in western blot (Fig. S2C,
left). Results are reported using the same format and meaning
of ‚Äún‚Äù and ‚Äúp‚Äù as for siRNA application. Treatment with 1 and
5 mM BAY11 changed proliferation in VS cells to 54.7  22.8%
(n ¬º 5, p ¬º 0.15, Figure 4A (b), B) and 14.3  9.7% (n ¬º 4,
p ¬º 0.002, Figure 4A (c), B) of the non-treated cells (NT,
Figure 4A (a)), respectively. The apoptotic rate changed from

1.1  0.27% (Figure 4C (a), D) in the NT VS cells to 36  13%
(n ¬º 7, p ¬º 0.06. Figure 4C (b), D) and 47  12% (n ¬º 8,
p ¬º 0.02, Figure 4C(c), D) in cells treated with 1 mM and 5 mM
BAY11, respectively.

change

signiÔ¨Åcantly, being

In the control SC cultures, normalized proliferation rates
100.0  34.7%,
did not
165.2  125.1% (p ¬º 0.70), 133.2  101.1% (p ¬º 0.69),
130.2  65.6% (p ¬º 0.78) for NT cells, 1 mM, 5 mM and 1 mM
BAY11, respectively (n ¬º 3, Figure 4B). SCs demonstrated
higher apoptosis only at the highest, 1 mM BAY11 treatment.
NT, 1 mM, 5 mM or 1 mM treated GAN cells exhibited apoptosis
rates of 2.0  0.9%, 1.0  0.7% (p ¬º 0.53), 0.7  0.7% (p ¬º 0.47)
and 36.5  26.5% (p ¬º 0.43), respectively (n ¬º 3, Figure 4D).
These control experiments suggest that 5 mM BAY11 has the
greatest therapeutic promise against VS without being toxic
to SCs.

BAY11 treatment also decreased HEI-193 cell survival in a
dose-dependent manner. HEI-193 cells had very high basal
proliferation rates of 84.9  11.7% (n ¬º 3). NT, 10 mM, 100 mM
and 1 mM BAY11 treated HEI-193 cells exhibited normalized
proliferation rates of 100.0  13.8%, 65.6  24.6% (n ¬º 5,

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

8

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

Figure 4 e NF-kB inhibitor BAY11-7082 leads to selective decrease in proliferation and survival of VS cells. A. Representative proliferation
images for primary VS cultures treated with (a) no treatment (NT), (b) 1 mM and (c) 5 mM BAY11-7082 (BAY11). BrdU in nuclei (red) marks
proliferating cells, S100 (green) marks schwannoma cells. B. QuantiÔ¨Åcation of proliferation changes after treatment with BAY11 at different
concentrations (given in mM) in primary VS cells, primary SCs and HEI-193 NF2 VS cell line, all normalized to proliferation in control NT cells
(n ‚Ä° 3). C. Representative cell death images are shown for primary VS cultures treated with (a) NT, (b) 1 mM and (c) 5 mM BAY11-7082 (BAY11).
TUNEL (green) in nuclei marks dying cells. D. QuantiÔ¨Åcation of cell death rate after treatment with BAY11 at different concentrations (given in
mM) in primary VS cells, primary SCs and HEI-193 NF2 VS cell line (n ‚Ä° 3). *p < 0.05, **p < 0.01, re [ compared to. Error bars represent SEM.
Nuclei are labeled with Hoechst (blue) in (A, C).

p ¬º 0.25), 9.1  4.9% (n ¬º 5, p ¬º 0.006) and 4.3  3.3% (n ¬º 5,
p ¬º 0.003), respectively (Figure 4B). NT, 1, 5, 10, 100 mM and
1 mM BAY11 treated HEI-193 cells exhibited apoptotic rates
of 1.3  0.8%, 1.3  0.5% (n ¬º 6, p ¬º 0.22), 1.9  1.2% (n ¬º 6,
p ¬º 0.26), 1.1  1.1% (n ¬º 5, p ¬º 0.63), 58.8  21.5% (n ¬º 5,
p ¬º 0.04) and 55.3  16.9% (n ¬º 5, p ¬º 0.02), respectively
(Figure 4D).

Clinically-relevant NF-kB inhibitor curcumin

3.5.
decreases proliferation and survival in cultured primary VS
cells, NF2 VS cell line and primary SCs

Curcumin, a natural, well-tolerated NF-kB inhibitor that is
currently used in many clinical trials for various neurological,
inÔ¨Çammatory and neoplastic diseases, ranging from Alz-
heimer‚Äôs disease to colon cancer (Hatcher et al., 2008), was

tested in VS cells. Treatment of curcumin signiÔ¨Åcantly
decreased the activity of the NF-kB pathway as shown by the
decrease of phosphorylated p65 in western blot (Fig. S2, right).
Results are reported using the same format and meaning of
‚Äún‚Äù and ‚Äúp‚Äù as for siRNA application. Proliferation decreased
in a dose-dependent manner in VS cultures, with VS cells
receiving NT, 5, 20 and 50 mM curcumin (Figure 5A (aed,
respectively)) exhibiting normalized proliferation rates of
100.0%  30.5%, 141.8%  95.2% (p ¬º 0.57), 23.0  20.9%
(p ¬º 0.03) and 9.8  5.3 (p ¬º 0.0005) (n ¬º 3, Figure 5B). Apoptosis
also increased in a dose-dependent manner, with VS cells
receiving NT, 5, 20 or 50 mM curcumin (Figure 5C (aed, respec-
tively)) exhibiting apoptotic rates of 0.3  0.1, 11.6  6.3%
(n ¬º 8, p ¬º 0.37), 1.8  1.0% (n ¬º 3, p ¬º 0.37) and 73.3  6.3%
(n ¬º 7, p ¬º 0.0005)
(Figure 5D). The effect of curcumin
treatment on apoptosis in VS cells was also investigated by

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

9

Figure 5 e Clinically-relevant NF-kB inhibitor curcumin leads to selective decrease in proliferation and survival of VS cells. A. Representative
proliferation images for primary VS cultures treated with (a) no treatment (NT), (b) 5, (c) 20, and (d) 50 mM curcumin. BrdU in nuclei (red) marks
proliferating cells. B. QuantiÔ¨Åcation of proliferation changes after treatment with curcumin at 5, 20, and 50 mM in primary VS cells, primary
Schwann cells and HEI-193 NF22 VS cell line, all normalized to proliferation in control NT cells (n ‚Ä° 3); C. Representative cell death images are
shown for primary VS cultures treated with (a) NT, (b) 5, (c) 20, and (d) 50 mM curcumin. TUNEL (green) marks dying cells. D. QuantiÔ¨Åcation of
cell death rate after treatment with curcumin at 5, 20, and 50 mM in primary VS cells, primary Schwann cells and HEI-193 NF2 VS cell line (n ‚Ä° 3).
*p < 0.05, **p < 0.01, re [ compared to. Error bars represent SEM. Nuclei are labeled with Hoechst (blue) in (A, C).

cleaved caspase-3 immunocytochemistry. The results demon-
strate a statistically signiÔ¨Åcant apoptosis-inducing effect of
50 mM curcumin in VS cells (n ¬º 3, p ¬º 0.02, Fig. S3B). Taken
together, these results suggest that the decrease of NF-kB by
curcumin may be the mechanism leading to apoptosis in VS
cells.

Surprisingly, in contrast to the seemingly well-tolerated
proÔ¨Åle for curcumin in humans, curcumin decreased prolifer-
ation and increased apoptosis in control SC cultures at con-
centrations comparable to those efÔ¨Åcacious in VS cultures.
Proliferation tended to decrease in a dose-dependent manner,
with SCs receiving NT, 5, 20, 50 mM curcumin exhibiting
100.0%  29.6%,
normalized
85.3  25.7% (n ¬º 4, p ¬º 0.33), 31.0  18.3% (n ¬º 4, p ¬º 0.13)
and 3.14% (n ¬º 1, p ¬º 0.04) (Figure 5B); the trend became signif-
icant only at the highest tested dose. Apoptosis had the same

proliferation rates

of

trend with the highest dose leading to a signiÔ¨Åcant increase in
cell death. NT, 5, 20 or 50 mM treated GAN cells exhibited
apoptotic rates of 0.6  0.2, 1.3  0.3% (n ¬º 4, p ¬º 0.16),
1.7  0.4% (n ¬º 4, p ¬º 0.31) and 52.2  14.9% (n ¬º 5, p ¬º 0.03)
(Figure 5D). Nonetheless, the doses up to 20 mM seemed selec-
tively cytostatic against primary VS cells.

Intriguingly, the HEI-193 cells were more susceptible to
curcumin than primary VS cells or healthy SCs. Proliferation
decreased drastically with dose increases: HEI-193 cells
receiving NT, 5, 20 or 50 mM curcumin exhibiting normalized
proliferation rates of 100.0%  0.2%, 95.0  1.6% (p ¬º 0.12),
0.4  0.4% (p ¬º 0.0001) and 2.3  2.3% (p ¬º 0.001) (n ¬º 3,
Figure 5B). Apoptosis increased drastically at 20 mM,
in
contrast to the primary VS cells exhibiting apoptosis at
50 mM. HEI-193 cells receiving NT, 5, 20 or 50 mM curcumin
exhibited apoptotic rates of 0.5  0.4, 0.3  0.1% (n ¬º 5,

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

10

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

p ¬º 0.32), 77.3  8.4% (n ¬º 3, p ¬º 0.02) and 97.8  1.5% (n ¬º 4,
p ¬º 0.00003) (Figure 5D).

4.

Discussion

signiÔ¨Åcant networks

Conducting the Ô¨Årst comprehensive network analysis of mol-
ecules implicated in VS pathobiology, we identiÔ¨Åed and vali-
dated NF-kB as a central regulator. We also found direct
interactors of NF-kB such as PDGF (Olson et al., 2007), which
have been implicated in VS progression, to be the hubs of
other
(Supplementary Table S1).
Although others have suggested that NF-kB is activated in
VS cells via upstream stimulation such as with p75 signaling
(Ahmad et al., 2014), we Ô¨Ånd that NF-kB is inherently highly
active in human VS tissue and derived primary VS cells. The
apparent disparity may be due to differences in detection
methods or sample processing. As all prior experiments had
been conducted on cultured cells and cell lines, we are the Ô¨Årst
to show that the aberrant NF-kB activation occurs also in the
freshly resected VS tissue and cannot be deemed an artifact
of culturing.

Our analysis of expression signatures of the downstream
NF-kB genes in VS suggests a unique NF-kB target gene pro-
gram in VS, as may be expected in pathologic inÔ¨Çammation
(Hoesel and Schmid, 2013). Since NF-kB is highly expressed
by immature SCs during development, progressively declining
from pre-myelinating SCs to near absence in mature myeli-
nating SCs (Nickols et al., 2003), our Ô¨Åndings are also consis-
tent with VSs exhibiting a gene expression proÔ¨Åle akin to
immature SCs (Hung et al., 2002a,b). Pre-existing upregulation
of NF-kB in VSs, along with a few deÔ¨Åning mutations in other
genes,
could enable neoplastic proliferation of non-
myelinating SCs.

Using a pre-clinical model of primary human VS cells, we
demonstrate potential therapeutic efÔ¨Åcacy of directly targeting
NF-kB via experimental and clinical inhibitors. Our work with
freshly harvested VS samples from different patients captures
the variability of NF-kB aberrance in different VSs. Our results
suggest that therapeutic targeting of NF-kB may be generally
effective against VSs, not only against a small subset of VSs.
By utilizing three different modalities to inhibit NF-kB: (1)
highly-speciÔ¨Åc siRNAs against the NF-kB p50 and p65, (2) a
pharmacologic inhibitor BAY11 and (3) a clinically-relevant,
natural inhibitor curcumin, we afÔ¨Årm NF-kB‚Äôs role in VS prolif-
eration and survival. We reinforce previous Ô¨Åndings that siRNA
mediated NF-kB knockdown in primary VS cells reduces prolif-
eration and survival (Ammoun et al., 2013), and expand on
them by using more clinically relevant inhibitors.

A small molecule NF-kB inhibitor BAY11 showed a high
level of efÔ¨Åcacy and speciÔ¨Åcity against VS cells. Although
BAY11 has been characterized as an effective inhibitor of
NF-kB by inhibiting IkK activation, recently BAY11 has been
recognized to target many other pro-inÔ¨Çammatory molecules,
including TNFa (Lee et al., 2012a,b). Future work is needed to
determine whether the therapeutic efÔ¨Åcacy of BAY11 against
VS cells is solely due to NF-kB inhibition. As BAY11 was not
cytotoxic in primary SCs and has been well tolerated in vivo
in murine tumor xenograft studies (Dewan et al., 2003), future

exploration of BAY11 against VS in animal models in vivo is
warranted.

Curcumin, a clinically relevant NF-kB inhibitor that has
been tested in many clinical trials (Hatcher et al., 2008),
inhibited proliferation and promoted apoptosis of both pri-
mary VS cells and HEI-193 VS cells. Curcumin‚Äôs greater effec-
tiveness against HEI-193 VS cells at a lower dose than
required for primary VS cells suggests a higher therapeutic ef-
Ô¨Åcacy against NF2-derived than sporadic VSs. The dosage
curve of curcumin resembles a previously established dosage
curve for HEI-193 cells in a study that focused on another mole-
cule through which curcumin may be acting: Hsp70 (Angelo
et al., 2011). A follow-up study by the same authors investi-
gating curcumin‚Äôs direct binding partners did not reveal the
NF-kB complex being a target in HEI-193 cells (Angelo et al.,
2013), although the authors had previously reported inhibition
of phosphorylation of Protein Kinase B (AKT), an upstream
regulator of NF-kB activation (Angelo et al., 2011; Bai et al.,
2009). This is in contrast to the large body of literature that
shows curcumin‚Äôs role as an NF-kB inhibitor, via inhibition of
TNFa-induced IkB degradation (Hatcher et al., 2008), and as a
general inhibitor of inÔ¨Çammation (Hatcher et al., 2008; Marin
et al., 2007). It is important to acknowledge that although cur-
cumin was found to be efÔ¨Åcacious against colon cancer and
Alzheimer‚Äôs disease in animal and human studies, therapeutic
and toxicity proÔ¨Åles of curcumin have not been comprehen-
sively elucidated (Burgos-Moron et al., 2010). Some clinical tri-
als have noted nausea and diarrhea in patients taking
curcumin (Burgos-Moron et al., 2010). Since the levels of curcu-
min that led to primary VS and SC death were comparable,
more research is required on curcumin‚Äôs toxicity proÔ¨Åle, best
formulation and administration methods and its efÔ¨Åcacy in
brain diseases. Importantly, however, curcumin has recently
been shown to have otoprotective effect against aminoglyco-
side toxicity and the associated hearing loss (HL)
(Salehi
et al., 2014). Since most VS patients present with HL, future
studies are needed to explore whether curcumin could atten-
uate both VS growth and the associated HL simultaneously.

By establishing aberrance of several molecules involved in
the NF-kB pathway and efÔ¨Åcacy of NF-kB inhibition selectively
in VS cells via several inhibitors, we demonstrate NF-kB as a
potential pharmacologic target against VS. However, possible
future clinical targeting of NF-kB has to be considered care-
fully given that NF-kB is an important signaling node that
most cells rely on.

ConÔ¨Çicts of interest

All authors have no conÔ¨Çicts of interest.

Funding

The funding sources were National Institute of Deafness and
Other Communication Disorders
to
K.M.S.; T32DC00038 to K.M.S., S.D.), Department of Defense
(W81XWH-14-1-0091 to K.M.S.) and the Bertarelli Foundation
(K.M.S.). The funding sources had no direct involvement in
this work.

(KO8DC010419-D1

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

11

Acknowledgments

We are grateful to Drs. Emerick, McKenna, Barker and Martuza
for assisting in specimen collection.

Appendix A.
Supplementary data

Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.molonc.2015.03.009.

R E F E R E N C E S

Aarhus, M., Bruland, O., S√¶tran, H.A., Mork, S.J., Lund-

Johansen, M., Knappskog, P.M., 2010. Global gene expression
proÔ¨Åling and tissue microarray reveal novel candidate genes
and down-regulation of the tumor suppressor gene CAV1 in
sporadic vestibular schwannomas. Neurosurgery 67,
998e1019.

Ahmad, I., Yue, W.Y., Fernando, A., Clark, J.J., Woodson, E.A.,

Hansen, M.R., 2014. p75NTR is highly expressed in vestibular
schwannomas and promotes cell survival by activating
nuclear transcription factor kappaB. Glia 62, 1699e1712.

Ammoun, S., Provenzano, L., Zhou, L., Barczyk, M., Evans, K.,

Hilton, D.A., HaÔ¨Åzi, S., Hanemann, C.O., 2013. Axl/Gas6/NFkB
signaling in schwannoma pathological proliferation, adhesion
and survival. Oncogene 33, 336e346.

Angelo, L.S., Maxwell, D.S., Wu, J.Y., Sun, D., Hawke, D.H.,

McCutcheon, I.E., Slopis, J.M., Peng, Z., Bornmann, W.G.,
Kurzrock, R., 2013. Binding partners for curcumin in human
schwannoma cells: biologic implications. Bioorg. Med. Chem.
21, 932e939.

Angelo, L.S., Wu, J.Y., Meng, F., Sun, M., Kopetz, S., McCutcheon, I.E.,

Slopis, J.M., Kurzrock, R., 2011. Combining curcumin
(diferuloylmethane) and heat shock protein inhibition for
neuroÔ¨Åbromatosis 2 treatment: analysis of response and
resistance pathways. Mol. Cancer Ther. 10, 2094e2103.

Archibald, D.J., Neff, B.A., Voss, S.G., Splinter, P.L.,

Driscoll, C.L.W., Link, M.J., Dong, H., Kwon, E.D., 2010. B7eH1
expression in vestibular schwannomas. Otol. Neurotol. 31,
991e997.

Bai, D., Ueno, L., Vogt, P.K., 2009. Akt-mediated regulation of NF-
kB and the essentialness of NF-kB for the oncogenicity of PI3K
and Akt. Int. J. Cancer 125, 2863e2870.

Dayalan, A.H.P.P., Jothi, M., Keshava, R., Thomas, R., Gope, M.L.,

Doddaballapur, S.K., Gope, R., 2006. Age dependent
phosphorylation and deregulation of p53 in human vestibular
schwannomas. Mol. Carcinog. 45 (1), 38e46.

Dewan, M.Z., Terashima, K., Taruishi, M., et al., 2003. Rapid tumor
formation of human T-cell leukemia virus type 1-infected cell
lines in novel NOD-SCID/^I3cnull mice: suppression by an
inhibitor against NF-kB. J. Virol. 77, 5286e5294.

Dilwali, S., Patel, P.B., Roberts, D.S., Basinsky, G.M., Harris, G.J.,

Emerick, K., Stankovic, K.M., 2014. Primary culture of human
Schwann and schwannoma cells: improved and simpliÔ¨Åed
protocol. Hear. Res. 315, 25e33.

Doherty, J.K., Ongkeko, W., Crawley, B., Andalibi, A., Ryan, A.F.,
2008. ErbB and Nrg: potential molecular targets for vestibular
schwannoma pharmacotherapy. Otol. Neurotol. 29, 50e57.

Gilmore, T., 2014. NF-kB Transcription Factors. http://

www.bu.edu/nf-kb/.

Hatcher, H., Planalp, R., Cho, J., Torti, F.M., Torti, S.V., 2008.

Curcumin: from ancient medicine to current clinical trials.
Cell Mol. Life Sci. 65, 1631e1652.

Hoesel, B., Schmid, J., 2013. The complexity of NF-kappaB

signaling in inÔ¨Çammation and cancer. Mol. Cancer 12, 86.

Hung, G., Li, X., Faudoa, R., Xeu, Z., Kluwe, L., Rhim, J.S.,

Slattery, W., Lim, D., 2002. Establishment and characterization
of a schwannoma cell line from a patient with
neuroÔ¨Åbromatosis 2. Int. J. Oncol. 20, 475e482.

Hung, G., Colton, J., Fisher, L., Oppenheimer, M., Faudoa, R.,
Slattery, W., Linthicum, F., 2002. Immunohistochemistry
study of human vestibular nerve schwannoma differentiation.
Glia 38, 363e370.

Karin, M., 1999. How NF-B is activated: the role of the IB kinase

(IKK) complex. Oncogene 18, 6867e6874.

Kim, J.Y., Kim, H., Jeun, S., Rha, S.J., Kim, Y.H., Ko, Y.J., Won, J.,

Lee, K., Rha, H.K., Wang, Y., 2002. Inhibition of NF-kappaB
activation by merlin. Biochem. Biophys. Res. Commun. 296,
1295e1302.

Kramer, F., St‚Ç¨over, T., Warnecke, A., Diensthuber, M., Lenarz, T.,

Wissel, K., 2010. BDNF mRNA expression is signiÔ¨Åcantly
upregulated in vestibular schwannomas and correlates with
proliferative activity. J. Neurooncol. 98 (1), 31e39.

Lassaletta, L., Martinez-Glez, V., Torres-Martƒ±n, M., Rey, J.A.,

Gavilan, J., 2009. cDNA microarray expression proÔ¨Åle in
vestibular schwannoma: correlation with clinical and
radiological features. Cancer Genet. Cytogenet. 194, 125e127.
Lee, J., Rhee, M.H., Kim, E., Cho, J.Y., 2012. BAY 11-7082 is a broad-

spectrum inhibitor with anti-inÔ¨Çammatory activity against
multiple targets. Mediators InÔ¨Çamm.

Lee, J.D., Kwon, T.J., Kim, U., Lee, W., 2012. Genetic and epigenetic

alterations of the NF2 gene in sporadic vestibular
schwannomas. PLoS One 7, e30418.

Bian, L., Tirakotai, W., Sun, Q., Zhao, W., Shen, J., Luo, Q., 2005.

Mahaley, M.S.J., Mettlin, C., Natarajan, N., Laws, E.R.J., Peace, B.B.,

Molecular genetics alterations and tumor behavior of sporadic
vestibular schwannoma from the People‚Äôs Republic of China.
J. Neurooncol. 73, 253e260.

Burgos-Moron, E., Calderon-Monta~no, J.M., Salvador, J., Robles, A.,

Lopez-Lazaro, M., 2010. The dark side of curcumin. Int. J.
Cancer 126, 1771e1775.

Caye-Thomasen, P., Borup, R., Stangerup, S., Thomsen, J.,

Nielsen, F.C., 2010. Deregulated genes in sporadic vestibular
schwannomas. Otol. Neurotol. 31 (2), 256e266.

CiofÔ¨Å, J.A., Yue, W.Y., Mendolia-Loffredo, S., Hansen, K.R.,

Wackym, P.A., Hansen, M.R., 2010. MicroRNA-21
overexpression contributes to vestibular schwannoma cell
proliferation and survival. Otol. Neurotol. 31, 1455e1462.
de Vries, M., Briaire-de Bruijn, I., Malessy, M.J.A., de Bru‚Ç¨ƒ±ne,
Sica, F.T., van, d.M., Hogendoorn, P.C.W., 2013. Tumor-
associated macrophages are related to volumetric growth of
vestibular schwannomas. Otol. Neurotol. 34, 347e352.

1990. Analysis of patterns of care of brain tumor patients in
the United States: a study of the Brain Tumor Section of the
AANS and the CNS and the Commission on Cancer of the ACS.
Clin. Neurosurg. 36, 347e355.

Marin, Y.E., Wall, B.A., Wang, S., et al., 2007. Curcumin

downregulates the constitutive activity of NF-kB and induces
apoptosis in novel mouse melanoma cells. Melanoma Res. 17,
274e283.

Nickols, J.C., Valentine, W., Kanwal, S., Carter, B.D., 2003.

Activation of the transcription factor NF-kappaB in Schwann
cells is required for peripheral myelin formation. Nat.
Neurosci. 6, 161e167.

Olson, C.M., Hedrick, M.N., Izadi, H., Bates, T.C., Olivera, E.R.,

Anguita, J., 2007. p38 mitogen-activated protein kinase
controls NF-kB transcriptional activation and tumor necrosis
factor alpha production through RelA phosphorylation
mediated by mitogen- and stress-activated protein kinase 1 in

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

12

M O L E C U L A R O N C O L O G Y X X X ( 2 0 1 5 ) 1 e1 2

response to Borrelia burgdorferi Antigens. Infect. Immun. 75,
270e277.

O‚ÄôReilly, B.F., Kishore, A., Crowther, J.A., Smith, C., 2004.

Correlation of growth factor receptor expression with clinical
growth in vestibular schwannomas. Otol. Neurotol. 25,
791e796.

Patel, A.K., Alexander, T.H., Andalibi, A., Ryan, A.F., Doherty, J.K.,
2008. Vestibular schwannoma quantitative polymerase chain
reaction expression of estrogen and progesterone receptors.
Laryngoscope 118, 1458e1463.

Plotkin, S.R., Merker, V.L., Halpin, C., Jennings, D., McKenna, M.J.,
Harris, G.J., Barker II, F.G., 2012. Bevacizumab for progressive
vestibular schwannoma in neuroÔ¨Åbromatosis type 2: a
retrospective review of 31 patients. Otol. Neurotol. 33,
1046e1052.

Saydam, O., Senol, O., W‚Ç¨urdinger, T, Mizrak, A., Ozdener, G.B.,

Stemmer-Rachamimov, A.O., Yi, M., Stephens, R.M.,
Krichevsky, A.M., Saydam, N., Brenner, G.J., BreakeÔ¨Åeld, X.O.,
2011. miRNA-7 attenuation in Schwannoma tumors
stimulates growth by upregulating three oncogenic signaling
pathways. Cancer Res. 71, 852e861.

Seol, H.J., Jung, H.W., Park, S.H., Hwang, S.K., Kim, D.G., Paek, S.H.,

Chung, Y.S., Sub Lee, C., 2005. Aggressive vestibular
schwannomas showing postoperative rapid growth e their
association with decreased p27 expression. J. Neurooncol. 75,
203e207.

Stankovic, K.M., Mrugala, M.M., Martuza, R.L., Silver, M.,

Betensky, R.A., Nadol Jr., J.B., Stemmer-Rachamimov, A., 2009.
Genetic determinants of hearing loss associated with
vestibular schwannomas. Otol. Neurotol. 30, 661e667.

Plotkin, S.R., Stemmer-Rachamimov, A., Barker, F.G., Halpin, C.,

Szeremeta, W., Monsell, E.M., Rock, J.P., Caccamo, D.V., 1995.

Padera, T.P., Tyrrell, A., Sorensen, A.G., Jain, R.K., di
Tomaso, E., 2009. Hearing improvement after bevacizumab in
patients with neuroÔ¨Åbromatosis type 2. N. Engl. J. Med. 361,
358e367.

Salehi, P., Akinpelu, O.V., Waissbluth, S., Peleva, E., Meehan, B.,
Rak, J., Daniel, S.J., 2014. Attenuation of cisplatin ototoxicity by
otoprotective effects of nanoencapsulated curcumin and
dexamethasone in a guinea pig model. Otol. Neurotol. 35,
1131e1139.

Sawaya, R., Highsmith, R., 1988. Plasminogen activator activity

and molecular weight patterns in human brain tumors.
J. Neurosurg. 68, 73e79.

Proliferation indicies of vestibular schwannomas by Ki-67 and
proliferating cell nuclear antigen. Otol. Neurotol. 16, 616e619.
Thomas, R., Prabhu, P.D.A., Mathivanan, J., Rohini, Sivakumar, D.,
Jayakumar, P.N., Devi, B.I., Satish, S., Sastry, K.V.R., Gope, R.,
2005. Altered structure and expression of RB1 gene and
increased phosphorylation of pRb in human vestibular
schwannomas. Mol. Cell. Biochem. 271, 113e121.

Welling, D.B., Lasak, J.M., Akhmametyeva, E., Ghaheri, B.,

Chang, L., 2002. cDNA microarray analysis of vestibular
schwannomas. Otol. Neurotol. 23, 736e748.

Please cite this article in press as: Dilwali, S., et al., Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit
human vestibular schwannoma growth, Molecular Oncology (2015), http://dx.doi.org/10.1016/j.molonc.2015.03.009

